Aripiprazol’a Bağlı Parkinsonizm: İki Olgu Sunumu

Year 2015, Volume: 16 Issue: 3, 124 - 127, 01.12.2015

Çetin Kürşad Akpınar Dursun Aygün Hakan Doğru Necdet Bolat

Abstract

Aripiprazoli şizofreni, depresyon, bipolar bozukluk ve parkinson hastalığında kullanılan yeni kuşak antipsikotiklerdendir. En iyi bilinen yan etkileri arasında insomni, anksiyete, baş ağrısı, bulantı, kusma ve somnolans yer alır. Aripiprazol sık olmayan ekstrapiramidal yan etkilerle ilişkilidir. Bazı ilaçların dopaminerjik reseptörleri blokajı sonucu parkinsonizm tablosu ortaya çıkabilmektedir. İlaca bağlı parkinsonizm de belirtiler genelde subakut yerleşir ve tabloya genel de akinetik-rijid bir sendrom hakim olur. Parkinsonizm belirtileri, kural olarak ilacın kesilmesiyle birkaç ay içinde kaybolur. Aripiprazol dopamin sistemini dengeleyici ilaçlar grubundadır, böylece daha az ekstrapiramidal yan etki profiline sahip olduğu öne sürülmektedir. Bu yazıda aripiprazol ilişkili parkinsonizmli iki olgu sunulmuştur

Keywords

Antipsikotik, aripiprazol, parkinsonizm, yan etki

Aripiprazole-Induced Parkinsonism: Report of Two Cases

Abstract

Aripiprazole is one of the recently introduced atypical antipsychotics used in the treatment of psychosis related to schizophrenia, depression, bipolar disorder, and Parkinson’s disease. Well-documented side effects associated with the use of aripiprazole include insomnia, anxiety, headache, nausea, vomiting, and somnolence. Aripiprazole is associated with infrequent extrapyramidal side effects. Parkinsonism is caused by some drugs that block dopamine receptors. The sign of drug-induced parkinsonism (DIP) has a subacute onset and the clinical picture is usually dominated by akinetic-rigid symptoms. The symptoms of parkinsonism generally disappear within a few months after cessation of the drug. Aripiprazole, a dopamine system stabilizer, has fewer extrapyramidal side effects than typical antipsychotics. In this paper, we present two cases of aripiprazole-induced parkinsonism.

Keywords

Antipsychotic, aripiprazole, parkinsonism, side effect

References

• 1. Kane JM, Carson WH, Saha A, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-71.
• 2. Sethi KD. Movement disorders induced by dopamine blocking agents. Semin Neurol 2001; 21: 59-68.
• 3. Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008; 23: 401-4.
• 4. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995; 3: 64-75.
• 5. Travis MJ, Burns T, Dursun S, Fahy T, Frangou S, Gray R, et al. Aripiprazole in schizophrenia:consensus guidelines. Int J Clin Pract 2005; 59: 485-95.
• 6. Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009; 256: 910-5.
• 7. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009; 85: 322-6.
• 8. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010; 81: 5-12.
• 9. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009; 85: 322-6.
• 10. Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007; 22: 1229-38.
• 11. Pasquier de Franclieu S, Germain C, Petitjean F. Aripiprazole induced Parkinsonism: A case report. Encephale. 2009; 35: 496-8.
• 12. Hall DA, Agarwal P, Griffith A, Segro V, Seeberger LC. Movement Disorders Associated with Aripiprazole Use: A Case Series. Int J Neurosci 2009; 119: 2274-9.
• 13. Sharma A, Sorrell JH. Aripiprazole-induced Parkinsonism. Int Clin Psychopharmacol. 2006; 21: 127-9.
• 14. Patel H, Patel A, Mushtaq S, Haq F, Raza S. Aripiprazole-induced parkinsonism in a child: a case report. Prim Care Companion CNS Disord. 2011; 13.
• 15. De Schutter P, Bouckaert F, Peuskens J. Aripiprazole-induced parkinsonism in a 64-year-old female patient diagnosed with bipolar disorder. Tijdschr Psychiatr. 2011; 53: 299-303